Glenmark Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The newly launched drug is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat oral solution of UCB, Inc.

Lacosamide is used to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures. It acts on the central nervous system (CNS) to reduce the number and severity of seizures.

According to IQVIA, sales data for the 12-month period ending October 2024, the Vimpat oral solution, market achieved annual sales of approximately $57 million.

Marc Kikuchi, president & business head of North America, said, “We are excited to announce the launch of Lacosamide oral solution, strengthening our commitment to bring to market quality and affordable alternatives for patients.”

Glenmark’s current portfolio includes 201 products authorized for distribution in the US marketplace and 51 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to further enhance and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses.

The drug maker reported consolidated net profit from continuing operations of Rs 354.49 crore in Q2 FY25 as against net loss of Rs 180.3 crore in Q2 FY24. Revenue from operations increased 2.29% year on year (YoY) to Rs 3,133.79 crore in the quarter ended 30 September 2024.

Shares of Glenmark Pharmaceuticals rose 0.83% to Rs 1,529.80 on the BSE.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Lacosamide Oral Solution, 10 mg/mL. Glenmark's Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat®2 Oral Solution, 10 mg/mL of UCB, Inc.

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat® Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1566.05, up 1.2% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Glenmark Pharmaceuticals Ltd has slipped around 7.84% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has slipped around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 1.32 lakh shares today, compared to the daily average of 6.95 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 1569.85, up 0.78% on the day. Glenmark Pharmaceuticals Ltd is up 101.88% in last one year as compared to a 18.09% jump in NIFTY and a 38.64% jump in the Nifty Pharma index.

The PE of the stock is 23.08 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

Travoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Travoprost is in a class of medications called prostaglandin analogs.

The newly launched drug is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Ophthalmic Solution USP of Sandoz, Inc.

According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Ophthalmic Solution USP, market achieved annual sales of approximately $66.2 million.

Jim Brown, senior vice president, sales & marketing said, “We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”

Glenmark currently has a portfolio of 200 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses.

The drug maker reported consolidated net profit from continuing operations of Rs 354.49 crore in Q2 FY25 as against net loss of Rs 180.3 crore in Q2 FY24. Revenue from operations increased 2.29% year on year (YoY) to Rs 3,133.79 crore in the quarter ended 30 September 2024.

The scrip shed 0.14% to Rs 1,519.10 on the BSE.

Powered by Capital Market - Live News